AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
January 19 2023 - 6:00PM
Business Wire
PTAB rejects third request by Berkeley Lights for invalidation
of AbCellera’s U.S. patents
AbCellera (Nasdaq: ABCL) today announced that the United States
Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB)
has ruled in favor of AbCellera in an Inter Partes Review (IPR)
filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged
AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).
AbCellera’s ‘408 Patent is directed to microfluidic devices and
using such devices to culture cells, monitor a response, and
recover selected cells.
The IPR proceeding stems from AbCellera and the University of
British Columbia (UBC) suing Berkeley Lights for patent
infringement currently pending in the United States District Court
for the Northern District of California. In response to AbCellera’s
infringement claims, Berkeley Lights filed three separate petitions
with the PTAB seeking to invalidate multiple patents. The PTAB
previously rejected two of Berkeley Lights’ petitions, disagreeing
that certain challenged claims were invalid. Berkeley Lights
challenged the claims of the ‘408 Patent alleging invalidity based
on anticipation and obviousness over the prior art. In response to
claims against the ‘408 patent, AbCellera and UBC opposed
institution and after oral argument, the PTAB rejected all of
Berkeley Lights’ arguments and confirmed that all claims of
AbCellera’s ‘408 Patent are valid.
“We are pleased with the PTAB’s decision, which reinforces the
validity and strength of our microfluidic cell culture system
patent claims,” said Tryn Stimart, JD, Chief Legal and Compliance
Officer of AbCellera. “Going forward, we will continue to
vigorously defend our intellectual property portfolio. With the IPR
outcomes, AbCellera intends to request that the district court
resume its patent infringement cases against Berkeley Lights.”
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce costs, and tackle the toughest problems in
drug development. For more information, please visit
www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230119005918/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.;
ir@abcellera.com, +1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Apr 2024 to May 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From May 2023 to May 2024